Alkaptonuria (AKU) is a rare autosomal recessive disease, affecting tyrosine metabolism. Patients accumulate homogentisic acid at 2000 times the normal rate, resulting in cartilage degradation and symptoms similar to early-onset osteoarthritis.
Self-Management - Alkaptonuria by Genetic Alliance UK 5 months ago
Robert McIver shares his story of managing Alkaptonuria, a genetic condition that only affects 1-4 people per million, from a rural area in Scotland.
Video by Genetic Alliance UK: www.genetic...
An American patient who was on Nitisinone by AKU Society UK 6 months ago
As you know I've had very longstanding medical and emotional issues due to the impact AKU has made on my life, family, marriage, and career. National Institutes of Health (NIH) in Bethesda MD, U.S.A in 2001 gave me the validation I needed to move forward in my life. That the pain was real, my numerous medical issues were real, and they informed me of my future and what I may expect.
In June 2005, I started participation in the long term clinical trial of Nitinisone. Happy Day! I had no complications whatsoever. NIH brought me back ...
Nick Sireau: Building the Alkaptonuria Movement Using the Web by AKU Society UK 6 months ago
6 months ago, Dr. Nick Sireau left his job to devote his efforts full time to finding a cure for a rare genetic disease called Alkaptonuria that effects his children. In this video, he describes...
Scientific meeting on AKU in Cardiff by AKU Society UK 7 months ago
The AKU Society is delighted to announce a meeting to discuss Alkaptonuria on 29 June 2011 in Cardiff.
It will be chaired by Prof James Leonard, Emeritus Professor of Metabolic Disease at the Institute of Child Health in London. This meeting will be held immediately before the Annual Symposium of the British Inherited Metabolic Disease Group (BIMDG), and will be jointly sponsored by Swedish Orphan Biovitrum Ltd and the AKU Society.
The meeting will be a scientific one, with an introduction from our research team in Liverpool on th...